Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.54/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
February 22, 2021 4:05 PM ESTHAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation (NPS) technology, today announced financial results for the fourth quarter and full year ended December 31, 2020.
Recent Highlights
Received U.S. Food and Drug Administration (FDA) clearance for the CellFX® System for dermatologic procedures requiring ablation and resurfacing of the skin Received CE mark approval for the CellFX System Initiated the CellFX System Controlled Launch program in the U.S. and Europe, including system implementations and completion of the first... More